Biologic Drug Effect and Particulate Embolization of Drug-Eluting Stents versus Drug-Coated Balloons in Healthy Swine Femoropopliteal Arteries.

[1]  R. Virmani,et al.  Safety of Zilver PTX Drug-Eluting Stent Implantation Following Drug-Coated Balloon Dilation in a Healthy Swine Model , 2018, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[2]  L. Fleisher,et al.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[3]  F. Farquharson,et al.  Acute hypersensitivity reaction to femoral drug-coated balloons. , 2017, VASA. Zeitschrift fur Gefasskrankheiten.

[4]  L. Fleisher,et al.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary , 2016, Circulation.

[5]  R. Virmani,et al.  Comparison of Particulate Embolization after Femoral Artery Treatment with IN.PACT Admiral versus Lutonix 035 Paclitaxel-Coated Balloons in Healthy Swine. , 2016, Journal of vascular and interventional radiology : JVIR.

[6]  S. Spiliopoulos,et al.  Comparative Effectiveness of Plain Balloon Angioplasty, Bare Metal Stents, Drug-Coated Balloons, and Drug-Eluting Stents for the Treatment of Infrapopliteal Artery Disease , 2016, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[7]  T. Ibrahim,et al.  Downstream Panniculitis Secondary to Drug-Eluting Balloon Angioplasty. , 2016, JACC. Cardiovascular interventions.

[8]  F. Castriota,et al.  1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study. , 2016, JACC. Cardiovascular interventions.

[9]  D. Scheinert,et al.  Drug-Coated Balloons for Complex Femoropopliteal Lesions: 2-Year Results of a Real-World Registry. , 2016, JACC. Cardiovascular interventions.

[10]  M. Dake,et al.  Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery , 2016, Circulation.

[11]  Hong Wang,et al.  Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA. , 2015, Journal of the American College of Cardiology.

[12]  D. Scheinert,et al.  Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. , 2015, The New England journal of medicine.

[13]  M. Shibuya,et al.  Impact of Paclitaxel Dose on Tissue Pharmacokinetics and Vascular Healing: A Comparative Drug-Coated Balloon Study in the Familial Hypercholesterolemic Swine Model of Superficial Femoral In-Stent Restenosis. , 2015, JACC. Cardiovascular interventions.

[14]  S. Spiliopoulos,et al.  Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. , 2014, JACC. Cardiovascular interventions.

[15]  G. Tepe,et al.  Drug-Coated Balloons vs. Drug-Eluting Stents for Treatment of Long Femoropopliteal Lesions , 2014, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[16]  A. Cannavale,et al.  Calcium Burden Assessment and Impact on Drug-Eluting Balloons in Peripheral Arterial Disease , 2014, CardioVascular and Interventional Radiology.

[17]  R. Varcoe,et al.  Vasculitis resulting from a superficial femoral artery angioplasty with a paclitaxel-eluting balloon. , 2014, Journal of vascular surgery.

[18]  Masataka Nakano,et al.  Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug‐coated balloon in a swine femoral artery model , 2014, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[19]  D. Scheinert,et al.  The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. , 2014, JACC. Cardiovascular interventions.

[20]  M. Dake,et al.  Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. , 2013, Journal of the American College of Cardiology.

[21]  T. Albrecht,et al.  Paclitaxel-Coated Balloons Reduce Restenosis After Femoro-Popliteal Angioplasty: Evidence From the Randomized PACIFIER Trial , 2012, Circulation. Cardiovascular interventions.

[22]  M. Dake,et al.  Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal Disease: Twelve-Month Zilver PTX Randomized Study Results , 2011, Circulation. Cardiovascular interventions.

[23]  M. Dake,et al.  Polymer-free paclitaxel-coated Zilver PTX Stents--evaluation of pharmacokinetics and comparative safety in porcine arteries. , 2011, Journal of vascular and interventional radiology : JVIR.

[24]  Dirk Mahnkopf,et al.  Dose Response to Paclitaxel-Coated Balloon Catheters in the Porcine Coronary Overstretch and Stent Implantation Model , 2011, Investigative radiology.

[25]  R. Virmani,et al.  Evaluation of Polymer-Based Comparator Drug-Eluting Stents Using a Rabbit Model of Iliac Artery Atherosclerosis , 2011, Circulation. Cardiovascular interventions.

[26]  B. Hamm,et al.  Inhibition of Restenosis in Femoropopliteal Arteries: Paclitaxel-Coated Versus Uncoated Balloon: Femoral Paclitaxel Randomized Pilot Trial , 2008, Circulation.